Complexity and redundancy of functional pathways controlled by the human genome explain that a single type of tumor can be induced by independant defective mutations in various genes that encode proteins acting in different parts of the cell physiology. Neuroendocrine tumors represent a powerful model for understanding such a complexity from the fact that at least six unrelated genetic syndromes have been characterized in the last decade which predispose to endocrine cell proliferation with variable penetrance and expressivity. Multiple Endocrine Neoplasia, von Hippel-Lindau, Carney and uncommonly Recklinghausen and Tuberous Sclerosis syndromes represent almost the whole panel of genetic diseases for which genes have been cloned and most of the functional knowledge has been collected. All the endocrine glands are concerned in these diseases, but the cellular pathways that are deregulated downstream from the deleterious mutations occurring in the genes of these autosomal dominant syndromes, might be related to each step of the cell life, from mitosis to DNA transcription, membrane receptor signalling and growth factor production, protein catabolism and extracellular matrix synthesis, and from transcription regulation to apoptosis and response to hypoxia and cellular stress. Here, we present an overview of genes involved in genetic predisposition to neuroendocrine tumors and highlight the complexity of pathways involved and the need of further studies focussing on genes involved in tumoral progression, most neuroendocrine tumors being benign at initial diagnosis but able to produce highly malignant cellular clones related to secondary genetic alterations or deregulation of growth factor production or cell-cell adhesion processes.
Introduction
Neuroendocrine tumors (NET) are uncommon diseases occurring sporadically or in a familial context of autosomal dominant inherited syndromes such as Multiple Endocrine Neoplasia (MEN). During the last decade, at least six major genes involved in initial steps of NET have been characterized, and one would expect that clinical screening syndromic forms of NET will include now genetic studies as a common tool for presymptomatic diagnosis [1] . Four major MEN syndromes are MEN1, MEN2, von Hippel-Lindau disease (VHL), and Carney Complex (CC), which represent the most common forms of inherited predisposition to NET with variable but high penetrance of proliferations in various neuroendocrine tissues. Less commonly, endocrine tumors of the pancreas, parathyroids and adrenal glands have been observed in phacomatosis, such as Recklinghausen disease (NF1) and Tuberous Sclerosis (TSC). Lastly, familial occurrence of a single endocrine lesion, such as primary hyperparathyroidism or pituitary adenoma have been identified as putative new genetic diseases for which genetic pathways remain to be identified. Most NET predisposing diseases were related to inactivation of growth suppressor genes, according to the Knudson model, except MEN2, an inherited form of medullary thyroid carcinoma, which occurs through dominant activation of a proto-oncogene, the RET tyrosine kinase receptor. Nevertheless, recent knowledge gamed about the biological role of most genes involved in cancer predisposition teaches us to that a single gene might have pleiotropic effects at various stages of the cell physiology, for instance both a negative and a positive regulator function depending on the cellular context and sometimes the type of mutation [2] .
Cloning of genes involved in genetic diseases predisposing to NET has led to a better insight in the molecular nature of tumor initiation of (neuro)endocrine tissues in mostly all endocrine glands. Even if the genes and related syndromes are presented separately, we would expect that genetic studies in patients with NET will now help differential diagnosis of syndromic diseases and that a single type of endocrine tumor may be related to the deregulation of distinct genes and related pathways. Major syndromes predisposing to NET and overlapping symptoms that lead to differential diagnosis by molecular genetic tools in some patients and/or families, are presented in Figure 1 . 
MENl, a major genetic context predisposing to NET

From the disease to the gene
Multiple Endocrine Neoplasia type 1 (MENl, OMIM 131100) is an autosomal dominant syndrome characterized by hyperplasia and/or multiple tumors of the parathyroid, endocrine pancreas, anterior pituitary, foregut-derived neuroendocrine tissues and adrenal cortical glands [3] . Less common lesions have been associated with MENl, including cutaneous proliferations such as angiofibroma, collagenoma, lipoma and melanoma [4, 5] , and peripheral or central nervous system tumors such as ependymoma [6, 7] . The MENl locus has been localized to chromosome Ilql3 in 1988 by linkage studies, and the MENl gene itself was identified in 1997 after a nine-year-long period of extensive positional cloning [8] [9] [10] . The MENl gene consists of 10 exons, the first of which is untranslated, spanning around 7-10 Kb of genomic sequence and encoding menin, a protein of 610 amino acids. A major menin 2,8 Kb transcript and the protein were expressed in most human tissues analyzed, the menin RNA presenting a striking 4,2 Kb large form, suggesting alternative promotor triggering and/or alternative splicing in 5', a question remaining unresolved to date [10] . Menin does not reveal homologies to any other known proteins nor includes consensus motifs from which the putative function of the protein could be deduced. Nevertheless, menin was characterized as a nuclear protein containing two nuclear localization signals (NLS) in exon 10 [11] , which have been functionally defined by in vitro expression of deletion constructs labelled by epitope-tagging with enhanced green fluorescent protein (EGFP). Despite the nuclear localization suggesting a major role of menin in the regulation of genome expression, the MENl protein was recently shown to move from nucleus to cytoplasm during the cell cycle, and mainly during the mitotic process [12] . These data contrast with the absence of any variation of size and amount of menin throughout the cell cycle as studied in synchronized cells [13] .
Major function of menin in normal and MENl-related conditions
The major function of the MENl gene product might be related to the ability of menin to bind JunD, a transcription factor belonging to the multimeric API transcription regulation complex [14] . Deletion constructs and natural mutants of menin have shown that interaction with JunD needs three major domains of the menin protein, the first 40 aminoacids of the N-terminal region and two central sequences at positions 139-242 and 323-428, respectively. The menin-JunD interaction seemed to be specific and established through the N-terminal sequences (amino acids 1-70) of JunD and a co-activator, JAB1, involved in the transcriptional regulation activity of JunD in the API complex [14] . Specific JunD missense mutants in the N-terminal domain failed to bind menin with a subsequent activation of their transcriptional activity, suggesting escape of menin control [15] . Wild-type menin repressed transcriptional activation, mediated by JunD upon in vitro co-transfection assays. Independently, some authors have confirmed these data and showed that menin mediated repression of JunD activity was related to histone deacetylation mechanisms, which are involved in chromatin-mediated regulation of gene expression [16] .
Despite extensive characterization of menin-JunD interaction, the physiopathogeny of MENl-related endocrine and non-endocrine lesions remains poorly understood, mainly considering the fact that API is an ubiquitous factor in all tissues, regulating most cellular process such as, mitosis, DNA replication, transcription, apoptosis and response to physical or chemical stress [1] . JunD was considered as a transcriptional activator but paradoxical observations showed that overexpression of JunD in NIH3T3 cells suppresses cell growth. This suggests that JunD might be both a corepressor and a co-activator in API, depending on the cellular context. Recent studies showed that overexpression of menin in ras-transformed NIH3T3 cells inhibits cell growth, supporting the hypothesis that menin is a growth-suppressor through complex interactions within the JunD-APl complex [17] .
More than 300 unique germline mutations have now been identified in MEN1 family probands analyzed throughout the world [18] [19] [20] [21] [22] [23] [24] . Somatic mutations have also been reported in sporadic forms of endocrine tumors with variable incidence of 20%-30% in parathyroid, endocrine pancreas (gastrinomas, insulinomas), lung carcinoids and less than 1% in pituitary and adrenal cortical tumors [25] [26] [27] [28] [29] [30] [31] [32] [33] . All these mutations were recently included in an unpublished mutation database developed in the frame of UMD (Universal Mutation database) software, allowing an easy evaluation of genotype-phenotype correlations [34] . Over 70% of germline mutations related to the MEN1 disease are nonsense and frameshifts predicting truncation and/or absence of the abnormal protein. Missenses, in-frame deletions or insertions and splice-site alterations account for the remaining «30% mutations described in the clinical context of MENL A putative effect of truncating mutations might be a premature degradation of the truncated menin through the protein catabolism pathway as suggested by the failure of Western-Blot detection of mutant protein in most cases analyzed [13] . These observations do not exclude a transient and abnormal effect of the truncated menin within the nucleus and cytoplasm, a question which will be further adressed by immunohistochemical competent monoclonal antibodies against menin. Intronic and splice-site mutations were shown to alter RNA splicing with abnormal exon skipping and/or intronic retention [24, 35, 36] .
Homologs ofMENl sequences in other species
The murine Men! gene was mapped and cloned in the pericentromeric region of murine chromosome 19 which is syntenic to human Ilql3 [37] . The genomic organization of Men] is similar to that of the human gene, including 10 exons and a noncoding region covering x 6,7 Kb of genomic DNA. Suggestive of what might happen in humans, two major transcripts of 2,8 and 3,2 Kb were detected in most embryonic and adult tissues, resulting from alternative splicing of intron 1 [38] . The predicted protein is 611 amino acids in length and characterized by 97% homology with the human sequence. Two independent teams subsequently cloned the murine and rat Menl and showed similar data on structure and expression [39, 40] . The expression of Men] is detected as early on gestational day 7 in the whole embryo, and a strong expression limited to thymus, liver, nervous system and gonads at day 17. Hence, the expression of Menl was not confined to organs affected in MENL In testis, Men] expression was found to be higher in Sertoli cells than in germ cells [37] . These data assess independant observations, suggesting that menin-JunD related pathways within the API complex might directly control the transition of granulosa cells to terminally differentiated, non-dividing luteal cells in the ovarian gland [41] . Lastly, the zebra fish and drosophila homologs of MEN] have been recently identified and show respectively x 75% and x 47% homologies with the human sequence [42, 43] . Among the amino acid residue substitutions reported as disease-associated missense mutations, most of them (^70%) were completely conserved, either in zebra fish and drosophila menin, indicating an evolutionary conserved protein with a fundamental role in biological processes.
Animal model ofMENl and pathogenic effect ofMENl gene inactivation
According to the Knudson model, MEN1 appears to be a growth suppressor gene with tumors in MEN1 affected patients showing somatic loss of the wild-type allele, socalled loss of heterozygosity (LOH) at Ilql3 [44, 45] . Functionally, all truncating mutations affect one or both NLS in the C-terminal domain of menin. Conversely, missense mutations have never been observed inside the menin NLSs sequences, suggesting that the functional role of these sequences might be critical for cell survival, mainly at the embryonic level. Recently, the first mouse model of MEN1 was produced through homologous recombination of the mouse Menl gene [46] . A major mice strain lacking exons 3-8 of the Menl gene was produced, and heterozygous Menl +/~ were bred to generate Menl" 7 " homozygotes. Homozygous inactivation of the Menl gene was lethal around days 10-14 of embryogenesis with developmental delay, defects in cranial and facial developments. Interestingly, Menl +/h eterozygotes developed hyperplastic pancreatic islets and first small tumors after 9 months and significantly larger tumors with capsular invasion after 16 months of age. Other tumors observed in heterozygous Menl +/m ice were parathyroid hyperplasia/adenoma, pituitary adenoma and adrenal cortical carcinomas, in 24%, 26% and 20% of cases analyzed throughout the course of the time study. Most of the tumor observed in this animal model showed loss of heterozygosity on the wild-type allele [46] .
Clinical implications of MENl gene analysis
Taken together, updated data on MENl suggest that inactivation or absence of both MENl alleles is a critical factor in MENl-related endocrine tumors initiation. Identification of nonsense or any other truncating mutations in a MENl suspected patient clearly assesses the diagnosis. With missense or intronic mutations, we might consider that pathogenic effects may be related to disturbances in menin-JunD (or forthcoming new functional interactions) related pathway or abnormal splicing respectively. In such cases, in vitro functional tests will be required to assess, for instance, that an amino acid substitution must be considered as a mutation and not a rare polymorphism. Clinical criteria used for diagnosis of MENl are crucial and in, our experience, MENl germline mutations were found in 95% of probands/families with patients sharing at least three major lesions of the syndrome and first-degree relatives affected by one (or more) MENl-related lesions [21] . Most families without demonstrable MENl mutations display an atypical clinical pattern, which might suggest genetic heterogeneity of the disease or the occurrence of phenocopies with lesions which are commonly observed in the non-MENl individuals, such as primary hyperparathyroidism and prolactinoma [47, 48] . Lastly, when MENl is strongly suspected, mutations might occur in unknown part of the MENl sequence, as the 5' regulatory region for which functional characterization is in progress [49] . Large intragenic rearrangements and/or deletions, either within or encompassing the MENl gene might have been missed by routine PCR and sequencing procedures. A MENl deletion has been suggested in a Japanese MENl pedigree by quantitative Southern-Blot analysis and has been shown recently in a large french MENl family using molecular cytogenetics procedures [50, Lespinasse et al., in preparation]. Finally, we might conclude that clinical screening of patients remains a prerequisite of genetic analysis and that functional knowledge on menin-related pathways must be kept in mind by clinicians following MENl-affected patients.
Oncogenic activation of RET, a tyrosine-kinase membrane receptor, induces MEN2
Clinical expression of RET germline mutations
The two major variants of Multiple Endocrine Neoplasia type 2 (MEN2A or Sipple's syndrome, OMIM 171400; MEN2B or Gorlin syndrome, OMIM 162300), result from missense activating (or oncogenic) mutations of RET, a gene localized on chromosome 10qll-2 and encoding a transmembrane tyrosine-kinase (TK) receptor [51, 52] , MEN2 might be considered as the inherited form of medullary thyroid carcinoma (MTC), a constant lesion in MEN2, associated or not with pheochromocytoma and/or primary hyperparathyroidism. MEN2B is a rare variant characterized by an earlyoccurrence and aggressive MTC, pheochromocytoma, mucosal neuromas on the gastrointestinal tract and a marfanoid habitus. FMTC (Familial isolated Medullary Thyroid Carcinoma) might be considered as the classical MENA syndrome with very low penetrance of pheochromocytoma and hyperparathyroidism [53, 54] .
Functional insights on the c-ret protein
RET genomic size is 60 Kb and the gene contains 21 exons [55] . The c-ret protein is characterized by an extracellular cysteine-rich homodimerization domain and an intracellular TK catalytic site. The N-terminal part of the extracellular region contains a cadherin-like domain which mediates calcium-dependant cell-cell adhesion. This receptor bounds at least four ligands, GDNF (Glial cell line Derived Neurotrophic Factor), neurturin, artemin and persephrin, all of them inducing homodimerization of the c-ret protein through the cysteine-rich region, thereby triggering the TK catalytic site [56, 57] . Intracellular events after ligand binding and c-ret dimerization involve cross-phosphorylation of TK domains and the downstream activation of Ras-MAPkinase and PI3/AKT transduction pathways [58, 59] . Biological properties of c-ret and ligands are related to the genesis of the peripheral and central nervous sytem and renal excretory tract. Strikingly, both GDNF~7ã nd c-ret"'"" knock-out mice share the same phenotype with an early death after birth, lack of neurons in the whole digestive tract and kidney agenesis [60] [61] [62] . The c-ret protein is highly expressed in many normal endocrine tissues, developing kidney and in human tumors of the neural crest derivatives, such as MTC, neuroblastoma and pheochromocytoma [63, 64] . Recently, it has been proven that a constitutively activated RET-MEN2A allele promotes cell survival in vitro in the absence of any growth factors, and that this effect might be controlled by a specific domain around c-ret tyrosine 1062 through the PI3/AKT/MAP kinase pathways [65] .
Germline RET mutations in MEN2 and downstream deregulated pathways
All germline mutations of RET observed in MEN2 were missense mutations affecting either the cystein-rich extracellular dimerization domain (exons 8 to 13) or intracellular TK catalytic sites (exons 15 and 16) [66, 67] . Genotype-phenotype correlations have been clearly established, mutations occurring in exons 8 to 14 mostly being related to MEN2A and FMTC variants, muta-tions observed in exons 15 and 16 always being related to a MEN2B phenotype. Conversely, transgenic mice expressing an activating MEN2A-related mutation in exon 11 develop bilateral MTC, as in humans, but never pheochromocytoma [68, 69] . Mutations occurring in exons 8 to 11 induce spontaneous homodimerization of the c-ret protein in absence of the ligand(s) [70] . Mutations described in exon 13 and 14 affect the catalytic site by inducing an inappropriate binding to substrates of the intracellular signalling pathway [70, 71] . Lastly, MEN2B-related mutations in exons 15 and 16 switch the substrate specificity of the c-ret TK from a membrane receptor towards an intracellular tyrosine-kinase, thus inducing abnormal signalling pathways [70, 72] .
Clinical implications of RET sequencing in MEN2
To date, germline RET mutations were found in x 100% of MEN2A, «90% of FMTC and «95-100% of MEN2B families. In terms of clinical use, we might conclude that routine screening of exons 8, 10, 11, 12, 13, 14, 15 and 16 of RET is now a useful tool for an accurate presymptomatic diagnosis in this disease. Germline RET mutations were also found in 5%-7% of sporadic cases of MTC [73, 74] , mostly in patients for which clinical and genetic information has been less informative at initial diagnosis, suggesting de novo mutations or missed familial cases. MEN2 syndrome represents a model in genetic predisposition to cancer by the fact that molecular genetic analysis of RET might be considered as an early preventive action, leading to prophylactic thyroidectomy in (young) asymptomatic gene-carriers [75] .
VHL gene and function
The VHL gene was cloned in 1993 on chro 3p35-36 and contains only three exons enc protein with pleiotropic functions [79] . The VH1 interacts with the elongin family involved as n of transcriptional elongation [80, 81] . Other fun the VHL protein have been related to the induced cell regulation by enhanced expre: VEGF (Vascular Endothelial Growth Factor) tion of extracellular matrix fibronectin expres: stabilization and, lastly, VHL protein intera Cullin-2 and Rbxl, two major components of t lar ubiquitination or protein catabolism machir 84]. Many naturally occurring mutations in V either been shown or are predicted to abrogate < with elongins and Cullin-2, suggesting a functii for these interactions in VHL-related tumors ai tive NET [85, 86] .
Clinical implications of VHL gene analysis
VHL gene sequencing has been useful in pre matic diagnosis of VHL disease and in some states suggesting differential diagnosis with MI MEN2. In fact, germline mutations of the Vi have been shown in patients with pancreatic ei tumors without any lesions, suggesting MEN1 in rare cases of familial occurrence of pheochro mas [88] . Carney complex and localized on 2pl6 remains to be identified.
Discussion
Apart from well-defined genes involved in genetic predisposition to NET, we were not able to show a common pathway leading to the proliferation of neuroendocrine cells. We might expect that various mechanisms occur depending the embryological origins of the organs concerned. Figure 2 summarizes the mechanisms related to MEN1, MEN2, VHL, CC and NF1/TSC mutations in the genetic syndromes described previously. The genetic mechanisms underlying malignant progression of benign neuroendocrine tumors remain unknown. Some genes, such as NF1 (Neurofibromatosis type 1) and TSC1/2 (Tuberous Sclerosis), have been suggested to be putative loci involved in tumoral progression from the fact that both genetic syndromes related to mutations in these genes, either Recklinghausen Neurofibromatosis (NF1) and Tuberous Sclerosis (TSC), might rarely predispose to endocrine tumors such as pheochromocytomas, primary hyperparathyrodism and pancreatic somatostatinomas or insulinomas [95, 96] . The NF1 (chromosome 17) and both TSC1 (chromosome 9) and TSC2 (chromosome 16) genes are involved in the membrane signal transduction pathway by acting as negative regulators of ras (NF1) or rab-5 (TSCl/2)-related small G-proteins [97, 98] . NF1, TSC1/2 disrupt GTP-ras or rab-5 complex and are considered as GTPase-activating proteins (GAP), an independant class of growth-suppressor genes.
Most cancers result from multistep scenarios and we might consider that many other genes are involved in the progression of benign NET towards a fully malignant phenotype. Mutations of well-known growth-suppressor or onco-genes, such as p53, Ki-RAS, HER2/NEU, C-MYC, N-MYC, N-RAS, C-JUN, PRAD-1, C-erbB2 have been excluded as major events in NET progression even if some studies showed upregulation of gene expression in tumor tissues [1] . Up-regulation of genes such as bcl-2, an apoptosis-regulating function and p53 or down or de-regulation of adhesion molecules such as CD44 have been suggested to be of importance as prognostic markers in pancreatic and bronchial carcinoid tumors [99] , Nuclear nm23 and Ki-67 proliferation-associated markers have also been considered as useful tools for valuable prognostic information and identification of patients at risk of disease-related death [100, 101] . Nevertheless, more hopes on this topic remain related to the identification of loci-specific loss of heterozygosity (LOH) mainly on chromosomes lp and lq [103] , 3p25-26 [102, 103] , Ilql3 and 18q [104, 105] . Loss of the MEN1 loci might induce latent genomic and/or chromosomal instability, as suggested by a few reports, but the basic mechanism leading to this instability has not been proven to date [1] . Most of the genes involved in such LOH's remain to be identified and their
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Growth factors Figure 2 . Schematic summary of the complexity of pathways involved in genetic predisposition to neuroendocrine tumors. All proteins, membrane receptors, pathways and interactions are detailed in the text. When designated by +, the gene involved in the syndrome (such as MEN2) acts as an oncogene with a dominant mechanism. When designated by -, the genes related to syndromes (such as MENl, NFl, TSC, Carney complex and VHL) are considered as growth suppressors, acting by negative regulation of various pathways shown in this figure. implications in neuroendocrine cell proliferation must be demonstrated by in vitro functional tests. Malignant progression of neuroendocrine tumors might also be triggered by overexpression of growth factors involved in endocrine and endothelial cell proliferation such as TGFa, EGF, NGF and VEGF/VEGF-related factors [106] [107] [108] [109] .
Finally, most of the genes involved in the initiation of endocrine tumors have now been discovered and are involved in genetic predisposition to NET. In sporadic and malignant forms of neuroendocrine tumors, other genes remain to be found and their respective roles during the multistep progression of tumors to be identified. Genetic studies have contributed to the development of animal models of neuroendocrine tumors in the context of genetic syndromes closed to what have been observed in humans. This represents a powerful tool for therapeutical assays in the future, mainly by understanding the mechanisms leading a normal endocrine cell towards a fully malignant and metastatic clone.
Acknowledgements
This work is a compilation of data from various authors working on NET and some projects performed in the frame of GENEM (Groupe d'Etude des Neoplasies Endocriniennes Multiples) and GETC (Groupe d'Etude des Tumeurs a Calcitonine). Genetic projects on MENl were supported by funds from a national contract coordinated by 'Hospices Civils de Lyon' (PHRC 97-048). C.V. was supported by the regional office referenced 'Comite de la Loire' of the 'Ligue Nationale contre le
